Molecular imaging in oncology drug development.
Tremendous breakthroughs are being made in cancer drug discovery and development. However, such breakthroughs come at a high financial cost. At a time when there is increasing pressure on drug pricing, in part because of increased life expectancy, it is more important than ever to drive new therapeutics towards patients as efficiently as possible. In this review we discuss the applications of molecular imaging in oncology drug development, with a focus on its ability to enable better early decision making, to increase efficiency and thereby to lower costs.
AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA. Electronic address: sarah.mudd@abbvie.com.
Sarah R
SR
Mudd
AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA.
Robert A
RA
Comley
Neuropharmacology, Uppsala, Sweden.
Mats
M
Bergstrom
AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA.
Kyle D
KD
Holen
AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA.
Yanping
Y
Luo
ICMUB - UMR CNRS 6302 Université Bourgogne-Franche Comté, France.
Sabin
S
Carme
AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA.
Gerard B
GB
Fox
AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA.
Laurent
L
Martarello
AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA.
John D
JD
Beaver
D000970:Antineoplastic Agents / Q000191:economics / Q000493:pharmacokinetics / Q000494:pharmacology; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D006801:Humans; D057054:Molecular Imaging / Q000191:economics / Q000379:methods*; D014018:Tissue Distribution
D000970:Antineoplastic Agents